Skip to main content

Day: June 9, 2021

Sinch AB (publ): Sinch announces revised financial leverage policy

Stockholm, Sweden – Sinch AB (publ) – XSTO: SINCH The Board of Sinch AB (publ) today announces a change to the company’s financial leverage policy. The new policy is as follows:Sinch’s target is that net debt over time shall be below 3.5 times adjusted EBITDA (measured on a rolling twelve month basis).The phrase ‘over time’ means that leverage may temporarily exceed the targeted level in the near term following an acquisition. Before today’s announcement, the policy was that net debt over time shall be below 2.5 times adjusted EBITDA (measured on a rolling twelve month basis). Sinch’s other financial targets remain unchanged:Growth in adjusted EBITDA per share shall be 20 per cent per year. Dividend policy: The Board continues to see good growth opportunities through acquisitions over the next few years, and therefore proposes that...

Continue reading

Allarity Therapeutics Publishes E-Poster Detailing the Molecular Pathways Covered by the Dovitinib-DRP® Companion Diagnostic

– Poster title: A novel drug response predictor (DRP®) mRNA biomarker for the multi tyrosine kinase inhibitor dovitinib – Poster provides new details of the DRP® companion diagnostic for dovitinib, its lead oncology pipeline asset Press release Hørsholm, Denmark (9 June 2021) Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces the publication of an e-Poster titled ‘A novel drug response predictor (DRP®) mRNA biomarker for the multi tyrosine kinase inhibitor dovitinib’ at the European Association for Cancer Research (EACR) 2021 Virtual Congress held from 9 – 12 June 2021. The e-Poster is also available on the Company’s website on: https://allarity.com/technology/scientific-publications The e-Poster describes Allarity’s latest research into the Company’s novel companion diagnostic for dovitinib, known as the Dovitinib-DRP®...

Continue reading

SCOR : Declaration made pursuant to Article L. 233-8-II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers

InformationJune 9, 2021Declaration made pursuant to Article L. 233-8-II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers Information relating to the total number of shares and voting rights comprising the share capital as of 31 May 2021Date Total number of shares1 comprising the share capital Theoretical number of voting rights231/05/2021 186 981 576 186 981 576* * * Contact details CommunicationsJérôme Guilbert+33 (0)1 58 44 79 19jguilbert@scor.com Investor RelationsOlivier Armengaud+33 (0)1 58 44 86 12oarmengaud@scor.com www.scor.com LinkedIn: SCOR        | Twitter: @SCOR_SE SCOR, a Global Tier 1 Reinsurer SCOR, the world’s fourth largest reinsurer, offers its clients a diversified and innovative range of solutions and services to control and manage risk. Applying...

Continue reading

Contract Development and Manufacturing Organization Market 2021 | Size, Share, Growth, Trends, Analysis, Competitive Landscape, Forecast Report

Top Players Covered in the Contract Development and Manufacturing Organization Market Research Report Are Catalent, Inc, Baxter, Vetter, Recipharm AB, Albany Molecular Research Inc. (AMRI), Thermo Fisher, Scientific Inc. (Patheon), Unither, DPT LABORATORIES LTD., NextPharma Technologies and other key market players. Pune, India, June 09, 2021 (GLOBE NEWSWIRE) — Global Contract Development and Manufacturing Organization Market Size| 2021 Covid-19 Impact On Healthcare Industry Global Analysis By Size, Trends, Growth, Share, Business, Key Players, Merger, Statistics, Competitive Landscape, And Regional Forecast To 2026 is latest study published by Fortune Business Insights. Global contract development and manufacturing organization market size is projected to reach USD 278.98 billion by the end of 2026. Mergers and acquisitions are...

Continue reading

Orion’s Clinical Trial Shows Significant Improvement for Chronic Pain Patients Using Virtual Reality Therapy

ORION CORPORATION PRESS RELEASE 9 JUNE 2021 at 12.00 noon EEST          Orion’s Clinical Trial Shows Significant Improvement for Chronic Pain Patients Using Virtual Reality Therapy A novel treatment, a digital therapeutics software solution for Chronic Pain (DTxP), has shown statistically significant benefit over passive (placebo) control and standard care interventions for fear of movement, patient clinical global impression of change (PGIC) and quality of life in adult patients with chronic low back pain (CLBP). Results from Orion Corporation’s pilot study ‘VIRPI’ were announced at the IASP 2021 Virtual World Congress On Pain. Results from the ‘VIRPI’ study in patients with CLBP showed that TSK score (Tampa Scale for Kinesiophobia assessing fear of movement) was significantly reduced at the end-of-intervention (EOI) for DTxP. Primary...

Continue reading

Result of the auction of treasury bills on 9 June 2021

Bids, sales, stop-rates and prices are presented in the table below:      ISIN Bid Mill. kr. (nominal) Sale Stop-rate (per cent) Pro-rata Price98 18262 DKT 01/09/21 III 1,260 1,000 -0.522 100 % 100.119098 18346 DKT 01/12/21 IV 760 560 -0.520 100 % 100.250598 18429 DKT 01/03/22 I 1,700 1,600 -0.520 100 % 100.381398 18502 DKT 01/06/22 II 740 640 -0.520 100 % 100.5154Total 4,460 3,800      The sale will settle 11 June 2021

Continue reading

Disclosure of the number of shares forming the capital and the number of voting rights as of 31 05 2021

DECLARATION DU NOMBRE D’ACTIONS COMPOSANT LE CAPITALET DU NOMBRE TOTAL DE DROITS DE VOTE AU 31 MAI 2021 Article L. 233-8-II du Code de CommerceArticle 223-16 du Règlement général de l’AMFNombre d’actions composant le capital social 223 008 066Nombre de droits de vote théoriques 266 293 493Nombre de droits de vote exerçables 266 147 479Cette déclaration est en ligne sur le site internet d’Elis www.elis.com DISCLOSURE OF THE NUMBER OF SHARES FORMING THE CAPITALAND OF THE TOTAL NUMBER OF VOTING RIGHTS AS OF 31 MAY 2021Total number of shares 223,008,066Theoretical number of voting rights 266,293,493Number of exercisable voting rights 266,147,479This disclosure is on Elis web site www.elis.com Contacts Nicolas Buron, Investor Relations Director – Phone: +33 1 75 49 98 30 – nicolas.buron@elis.comAttachment...

Continue reading

PGS Delivers Rejuvenated Data for Santos West

June 9, 2021 PGS has revitalized 3D data over the Bauna field in southwest Santos Basin and its surrounding area. This preprocessed dataset is now available for evaluation of blocks for Brazil’s upcoming Permanent Offer Round. The data rejuvenation of legacy survey BM-S-40 started from field tapes and applied the latest workflow for data conditioning, noise, and multiple suppression to create a new 2500 sq. km preprocessed dataset.  The results, now available, can be input into new model building and imaging workflows, allowing a quicker evaluation of opportunities in the area. This is good news for companies that would like to nominate blocks in an area that is part of Brazil’s Permanent Offer Bid Round.  Using a subset of the preprocessed data, PGS has also produced a high-resolution PSTM over the Bauna field. PGS Santos...

Continue reading

Cornish Metals Releases Updated Mineral Resource Estimate for South Crofty Tin Mine

Indicated Resource Increases 10.2% to 2.08 Mt Grading 1.59% Tin for the Lower Mine Inferred Resource Increases 129.8% to 1.94 Mt Grading 1.67% Tin for the Lower Mine VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) — Cornish Metals Inc. (TSX-V/AIM: CUSN) (“Cornish Metals” or the “Company”), a mineral exploration and development company focused on its projects in Cornwall, United Kingdom, is pleased to announce the results of an updated Mineral Resource Estimate (“MRE”) for South Crofty in accordance with the JORC Code (2012). The Mineral Resource is divided into the “Lower Mine” and “Upper Mine” areas for reporting purposes. A summary of the updated MRE is tabulated below:South Crofty Summary Mineral Resource EstimateArea Classification Mass(000’ tonnes) Grade Contained Tin / Tin Equivalent(000’ tonnes) Increase...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.